Losing weight after a years-long struggle, this letter writer gave credit to the method — then came the judgmental comments.

The 74-year-old, who served as an FDA commissioner from 1990 to 1997, turned to GLP-1 medications after battling his weight ...

A new study has found GLP-1s may reduce the risk of developing obesity-related cancers by 41% compared to bariatric surgery — a benefit researchers believe could be tied to the drugs’ ability to ...

Federal regulators have accepted Novo Nordisk’s application to produce a pill version of its injectable weight-loss ...

U.S.-based Waters Corp , which makes medical equipment used in clinical testing, has seen a spurt in demand from drugmakers ...

As the FDA halts the sale of Ozempic and Zepbound copycats, online clinics have begun offering liraglutide, an older GLP-1 ...

Less than 3% of all people in the U.S. who are eligible for injectable weight loss drugs get a prescription for it, a new ...

California would scale back state Medicaid coverage for immigrants without legal status, eliminate coverage for certain ...

New research published in the American Journal of Health-System Pharmacy suggests a possible link between the GLP-1 drug ...

In a 72-week trial, people taking Zepbound lost 50 pounds on average, compared with about 33 pounds for people taking Wegovy.

The millions of people living with obesity need novel treatment options that are safe, effective and avoid the high costs and ...

Popular diabetes and weight loss drugs like Ozempic and Wegovy do not increase the risk of depression, anxiety or suicidal ideation, a new study finds.In fact, ...